Senti Biosciences, Inc.

Ownership Transactions Reported by 20 Insiders

Symbol
SNTI on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
2 Corporate Drive, First Floor, South San Francisco, CA

There are no Buy or Sell transactions made by insiders since 11/4/2023

Senti Biosciences, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Mark Afrasiabi Chief Financial Officer May 25, 2021
Mostafa Ronaghi Chief Executive Officer, Director May 25, 2021
Dipchand Nishar Director May 25, 2021
Dynamics Sponsor LLC Director, 10%+ Owner Jun 8, 2022
Rowan E. Chapman Chief Business Officer May 25, 2021
Jay T. Flatley Director May 25, 2021
Edward T. Mathers Director Jul 10, 2024
Omid Farokhzad Director Jul 10, 2024
James J. Collins Director Jul 10, 2024
Timothy K. Lu CEO and President, Director Feb 1, 2024
Yvonne Li Interim CFO May 4, 2024
Deborah Knobelman Chief Financial Officer, Head of Corporate Development Feb 1, 2024
Brenda Cooperstone Director Jul 10, 2024
Philip J. Lee Chief Technology Officer Feb 1, 2023
Susan D. Berland Director Jun 16, 2023
David R. Epstein Director Jul 13, 2022
Bayer Healthcare Llc 10%+ Owner Jun 8, 2022
Kanya Rajangam Chief Medical & Devt. Officer Feb 1, 2024
Curt A. Herberts III Chief Operating Officer Jun 8, 2022
New Enterprise Associates 15, L.P. 10%+ Owner Jun 8, 2022

Recent Insider Transactions by Companies or Individuals for Senti Biosciences, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.